In-Press Preview Research ArticleOncologyTherapeutics Free access | 10.1172/JCI98727
Find articles by Liu, Y. in: JCI | PubMed | Google Scholar
Find articles by Xu, H. in: JCI | PubMed | Google Scholar
Find articles by Jeught, K. in: JCI | PubMed | Google Scholar
Find articles by Li, Y. in: JCI | PubMed | Google Scholar
Find articles by Liu, S. in: JCI | PubMed | Google Scholar
Find articles by Zhang, L. in: JCI | PubMed | Google Scholar
Find articles by Fang, Y. in: JCI | PubMed | Google Scholar
Find articles by Zhang, X. in: JCI | PubMed | Google Scholar
Find articles by Rodovich, M. in: JCI | PubMed | Google Scholar
Find articles by Schneider, B. in: JCI | PubMed | Google Scholar
Find articles by He, X. in: JCI | PubMed | Google Scholar
Find articles by Huang, C. in: JCI | PubMed | Google Scholar
Find articles by Zhang, C. in: JCI | PubMed | Google Scholar
Find articles by Wan, J. in: JCI | PubMed | Google Scholar
Find articles by Ji, G. in: JCI | PubMed | Google Scholar
Find articles by Lu, X. in: JCI | PubMed | Google Scholar
First published April 12, 2018 - More info
Synthetic lethality-based strategy has been developed to identify therapeutic targets in cancer harboring tumor suppressor gene mutations, as exemplified by the effectiveness of PARP inhibitors in BRCA1/2-mutated tumors. However, many synthetic lethal interactors are less reliable due to the fact that such genes usually do not perform fundamental or indispensable functions in the cell. Here we developed an approach to identify the “essential lethality” arose from these mutated/deleted essential genes, which are largely tolerated in cancer cells due to genetic redundancy. We uncovered the cohesion subunit SA1 as a putative synthetic-essential target in cancers carrying inactivating mutations of its paralog, SA2. In SA2-deficient Ewing sarcoma and bladder cancer, further depletion of SA1 profoundly and specifically suppressed cancer cell proliferation, survival and tumorigenic potential. Mechanistically, inhibition of SA1 in the SA2-mutated cells led to premature chromatid separation, dramatic extension of mitotic duration, and consequently lethal failure of cell division. More importantly, depletion of SA1 rendered those SA2-mutated cells more susceptible to DNA damage, especially double-strand breaks (DSBs), due to reduced functionality of DNA repair. Furthermore, inhibition of SA1 sensitized the SA2-deficient cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with SA2-deficient tumors.